The primary objective of this study is to evaluate the efficacy of multiple-dose HSK47388 versus placebo in participants with moderate-to-severe plaque psoriasis.
Confirmed diagnosis of plaque psoriasis with a disease duration of at least 26 weeks before the first administration of the study intervention
Total Body Surface Area (BSA) involvement ≥ 10% at both screening and baseline visits
Psoriasis Area and Severity Index (PASI) total score ≥ 12 at both screening and baseline visits
Investigator Global Assessment (IGA) for plaque psoriasis total score ≥ 3 (moderate or severe disease) at both screening and baseline visits
Non-plaque psoriasis (e.g., erythrodermic, guttate, or pustular psoriasis)
Current drug-induced psoriasis
Current diagnosis, signs, or symptoms of severe, progressive, or uncontrolled disease involving the renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic systems
Known allergy, hypersensitivity, or intolerance to HSK47388。